These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 24700748)

  • 41. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
    Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.
    Zeven K; De Groof TWM; Ceuppens H; Awad RM; Ertveldt T; de Mey W; Meeus F; Raes G; Breckpot K; Devoogdt N
    Front Immunol; 2023; 14():1268900. PubMed ID: 37799715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.
    Nedrow-Byers JR; Moore AL; Ganguly T; Hopkins MR; Fulton MD; Benny PD; Berkman CE
    Prostate; 2013 Mar; 73(4):355-62. PubMed ID: 22911263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and Evaluation of
    Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of
    Carpanese D; Ferro-Flores G; Ocampo-Garcia B; Santos-Cuevas C; Salvarese N; Figini M; Fracasso G; De Nardo L; Bolzati C; Rosato A; Meléndez-Alafort L
    Sci Rep; 2020 Jun; 10(1):9313. PubMed ID: 32518372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
    Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
    Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-PSMA
    Frigerio B; Morlino S; Luison E; Seregni E; Lorenzoni A; Satta A; Valdagni R; Bogni A; Chiesa C; Mira M; Canevari S; Alessi A; Figini M
    J Exp Clin Cancer Res; 2019 Jul; 38(1):326. PubMed ID: 31337429
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
    Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
    Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
    Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
    Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
    J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
    Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
    Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
    Rosenfeld L; Sananes A; Zur Y; Cohen S; Dhara K; Gelkop S; Ben Zeev E; Shahar A; Lobel L; Akabayov B; Arbely E; Papo N
    J Med Chem; 2020 Jul; 63(14):7601-7615. PubMed ID: 32442375
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
    Nováková Z; Foss CA; Copeland BT; Morath V; Baranová P; Havlínová B; Skerra A; Pomper MG; Barinka C
    Prostate; 2017 May; 77(7):749-764. PubMed ID: 28247415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.